FDA Approves New KYPROLIS® (carfilzomib) Combination Regimen With DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and dexamethasone For Patients With Multiple Myeloma At First Or Subsequent Relapse| Amgen
Amgen's KYPROLIS (carfilzomib) received FDA approval for use with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) and dexamethasone to treat relapsed or refractory multiple myeloma. The approval was supported by the PLEIADES trial, which showed an 84.8% overall response rate. Amgen plans to submit global marketing applications.
How this was made
The 30-second read
Why it matters
The regulatory clearance adds a convenient, potentially higher‑adoption treatment option, likely boosting Amgen's oncology revenue outlook.
Market read
First‑report FDA approval creates a clear catalyst for Amgen's stock and may influence the broader cancer‑therapy market.
What to watch
Reimbursement negotiations and competition from other CD38 antibodies could limit upside.
Background
Amgen announced the FDA's expansion of KYPROLIS (carfilzomib) prescribing information to include a subcutaneous daratumumab regimen for relapsed/refractory multiple myeloma.
Ticker impact
FDA approved expanded use of KYPROLIS with DARZALEX FASPRO and dexamethasone for relapsed multiple myeloma.
likely upside as market prices in broader indication and potential sales growth
First‑report FDA approval; material to Amgen's revenue and pipeline, prompting buying interest.
Market effects
Strengthens the multiple‑myeloma treatment segment and may pressure peers such as Janssen and Celgene.
U.S. biotech sector could see modest gains on the back of the approval.
Highlights FDA's willingness to expand subcutaneous antibody combos, relevant for global oncology developers.
Counterpoint
If safety concerns or pricing issues emerge, the approval may not translate into meaningful sales.
Key entities
- CompanyAmgen
US biotech firm receiving FDA approval.
- DrugDARZALEX FASPRO
Subcutaneous daratumumab formulation co‑administered with KYPROLIS.
